NCT03092739View on ClinicalTrials.gov

A Study to Assess Programmed Death Ligand-1 (PD-L1) Expression in Cytological Versus Histological Lung Cancer Specimens

CompletedOBSERVATIONAL
Enrollment

184

Participants

Timeline

Start Date

May 3, 2017

Primary Completion Date

January 8, 2018

Study Completion Date

June 6, 2018

Conditions
Carcinoma, Non-Small-Cell LungCarcinoma, Small Cell
Interventions
DIAGNOSTIC_TEST

PD-L1 Immunocytochemistry (ICC)

PD-L1 expression in the cytological specimens will be assessed using different antibodies.

DIAGNOSTIC_TEST

PD-L1 Immunohistochemistry (IHC)

PD-L1 expression in the histological specimens will be assessed using different antibodies.

Trial Locations (8)

4031

Universitätsspital Basel; Pathologie, Basel

15006

Complejo Hospitalario Universitario A Coruña (CHUAC); Servicio de Anatomía Patológica, A Coruña

28046

Hospital Universitario La Paz; Servicio de Anatomia Patologica, Madrid

28050

HOSPITAL DE MADRID NORTE SANCHINARRO- C. INTEGRAL ONC. CLARA CAMPAL; Servicio Anatomia Patologica, Madrid

37075

Universitätsklinikum Göttingen, Institut für Pathologie, Göttingen

128 08

Vseobecna fakultni nemocnice v Praze; I. klinika tuberkulozy a respiracnich nemoci, Prague

01-138

Instytut Gruźlicy i Chorób Płuc, I Klinika Chorób Płuc, Warsaw

AB25 2ZN

Aberdeen Royal Infirmary, Aberdeen

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT03092739 - A Study to Assess Programmed Death Ligand-1 (PD-L1) Expression in Cytological Versus Histological Lung Cancer Specimens | Biotech Hunter | Biotech Hunter